GSK (GSK) said Friday that China's National Medical Products Administration has approved Trelegy Ellipta for the treatment of adults with uncontrolled asthma, expanding the drug's use beyond its existing chronic obstructive pulmonary disease indication.

The approval makes Trelegy the only single inhaler triple therapy approved in China for the maintenance treatment of both asthma and COPD, the company said.